뇌졸중 신규 치료법 보고서(2026년)(2분기판)

The Global Stroke Emerging Therapies Market is projected to grow at a CAGR of 9.1% during the forecast period, increasing from USD 2.84 billion in 2026 to USD 6.23 billion by 2035.

Pharmaceutical companies, biotechnology firms, and academic research organizations are actively developing next-generation therapies that aim to improve neurological recovery, extend treatment windows, reduce long-term disability, and address the significant unmet medical needs associated with ischemic and hemorrhagic stroke.

Stroke remains one of the leading causes of mortality and disability worldwide. Although thrombolytic therapy and mechanical thrombectomy have significantly improved acute stroke management, many patients remain ineligible for these interventions because of narrow treatment windows or delayed hospital presentation. Emerging therapies are increasingly focused on neuroprotection, neuroregeneration, stem cell therapy, inflammation modulation, vascular repair, and combination treatment strategies designed to improve both acute and long-term outcomes. Emerging therapies analysis provides valuable insights into pipeline innovations, clinical development progress, mechanisms of action, sponsor activities, competitive positioning, and future commercialization opportunities.

Market Drivers

Rising Global Stroke Burden

The increasing prevalence of stroke associated with aging populations, hypertension, diabetes, obesity, atrial fibrillation, and other cardiovascular risk factors continues to accelerate demand for innovative treatment options. The growing healthcare and economic burden of stroke is encouraging sustained investment in neurological drug development.

Expansion of Neuroprotective Therapies

Neuroprotective therapies are emerging as one of the most promising areas of stroke research. Investigational agents aim to minimize neuronal injury during ischemia, preserve brain tissue, and improve long-term functional recovery when used alongside standard reperfusion therapies.

Growth in Regenerative Medicine

Stem cell therapies, gene therapies, and regenerative medicine approaches are gaining momentum as researchers seek to restore damaged neural tissue and enhance neurological recovery after stroke. These therapies have the potential to address long-term disability beyond acute intervention.

Advances in Precision Medicine

Artificial intelligence, advanced neuroimaging, biomarker-guided patient selection, and personalized therapeutic strategies are improving clinical trial design and supporting the development of targeted stroke therapies.

Market Restraints

Complex Disease Biology

Stroke involves multiple pathological pathways, making development of universally effective therapies particularly challenging. Clinical heterogeneity contributes to high development risk and variable treatment responses.

High Clinical Development Costs

Emerging stroke therapies require extensive multicenter clinical trials, advanced imaging, long-term neurological assessments, and large patient populations, increasing both development cost and timelines.

Strict Regulatory Standards

Regulatory agencies require compelling evidence demonstrating meaningful improvements in neurological recovery, functional independence, and long-term safety before approving novel stroke therapies.

Emerging Therapy and Technology Insights

The global stroke emerging therapies market can be segmented by therapy type, development phase, stroke type, mechanism of action, route of administration, end user, and geography.

By therapy type, the market includes neuroprotective therapies, regenerative medicine, stem cell therapies, gene therapies, anti-inflammatory therapies, thrombolytic therapies, and combination therapies. Neuroprotective therapies currently represent the largest area of innovation, while regenerative medicine and stem cell approaches continue to gain significant research attention because of their potential to improve long-term neurological recovery.

By development phase, emerging therapies span preclinical research, Phase I, Phase II, Phase III, and regulatory review. Phase II and Phase III programs account for much of the current development activity as sponsors evaluate safety, efficacy, and functional outcomes in larger patient populations.

By stroke type, research covers ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke remains the dominant focus because it accounts for the majority of global stroke cases and presents the greatest opportunity for therapeutic innovation.

By mechanism of action, emerging therapies target neuroprotection, inflammation modulation, vascular repair, mitochondrial stabilization, cellular regeneration, excitotoxicity inhibition, and neuronal recovery. Increasingly, sponsors are evaluating combination therapies that complement thrombolysis or mechanical thrombectomy to maximize functional recovery.

By route of administration, investigational therapies include intravenous, oral, injectable, intra-arterial, and cell-based delivery approaches. Intravenous administration remains central to acute intervention, while regenerative therapies introduce novel delivery strategies.

Technological advances such as artificial intelligence-assisted imaging, biomarker-guided treatment selection, adaptive clinical trial designs, digital health platforms, wearable monitoring systems, and precision medicine are improving therapy development and accelerating clinical research.

Emerging Therapy Trends

The stroke therapeutic landscape continues to shift toward personalized and mechanism-based treatment strategies.

Key trends include:

• Expansion of neuroprotective drug development.
• Increasing investment in regenerative medicine.
• Growing clinical evaluation of stem cell therapies.
• Development of combination therapies alongside thrombectomy.
• Broader use of artificial intelligence in drug discovery.
• Increasing adoption of precision medicine approaches.
• Expansion of biomarker-guided clinical development.

Regional Insights

North America remains the leading region for emerging stroke therapies because of advanced neurological research infrastructure, substantial pharmaceutical investment, strong academic collaborations, and supportive regulatory pathways. The United States continues to lead late-stage clinical development and commercialization activities.

Europe maintains a strong position through multinational clinical research networks, comprehensive stroke care systems, and active participation in regenerative medicine and precision neurology research. Collaborative development programs continue to strengthen therapeutic innovation.

Asia-Pacific is expected to witness the fastest growth owing to rising stroke incidence, expanding healthcare infrastructure, increasing clinical trial activity, and growing investment in neurological research across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually increasing participation in multinational clinical studies through expanding research capabilities, healthcare modernization, and improved stroke management infrastructure.

Competitive Landscape

The stroke emerging therapies landscape includes multinational pharmaceutical companies, biotechnology firms, regenerative medicine developers, academic research institutions, and emerging neuroscience companies.

Organizations continue investing in neuroprotective agents, stem cell therapies, gene therapies, anti-inflammatory drugs, regenerative medicine, artificial intelligence, and precision medicine. Strategic collaborations, licensing agreements, mergers and acquisitions, and co-development partnerships remain essential strategies for accelerating innovation and strengthening competitive positioning.

Future Outlook

The future of stroke emerging therapies will be driven by advances in precision neurology, regenerative medicine, artificial intelligence, digital health, and personalized therapeutics. Continued innovation in neuroprotection, stem cell biology, vascular repair, biomarker-guided treatment selection, and adaptive clinical trial design is expected to accelerate commercialization of next-generation therapies.

Increasing integration of real-world evidence, digital health technologies, and combination therapeutic approaches will further improve treatment outcomes and create significant commercial opportunities through 2035.

Conclusion

The global Stroke Emerging Therapies Analysis highlights a rapidly evolving innovation landscape supported by increasing neurological research investment, advances in neuroprotective and regenerative medicine, expanding precision medicine capabilities, and growing adoption of artificial intelligence. Although challenges related to complex disease biology, clinical development, and regulatory requirements remain, continued advances in neuroscience and personalized therapeutics are expected to significantly improve patient outcomes while creating substantial opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive analysis of the global stroke emerging therapies landscape.
• Detailed evaluation of investigational therapies, mechanisms of action, and clinical development progress.
• Competitive assessment of pipeline innovation, strategic collaborations, and commercialization activities.
• Insights into regulatory developments, technology trends, and future therapeutic opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, investors, researchers, consultants, and policymakers.

What Businesses Use Our Reports For

Pipeline assessment, competitive intelligence, clinical development planning, licensing and partnership evaluation, portfolio optimization, investment analysis, regulatory strategy, commercialization planning, and strategic business decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global stroke emerging therapies landscape by therapy type, development phase, stroke type, mechanism of action, route of administration, end user, and geography
• Evaluation of emerging therapeutic candidates, clinical development progress, mechanisms of action, sponsor landscape, regulatory trends, and commercialization potential
• Assessment of strategic collaborations, licensing agreements, mergers and acquisitions, competitive positioning, and technology innovation
• Analysis of neuroprotective therapies, regenerative medicine, stem cell therapies, gene therapies, anti-inflammatory agents, precision medicine, artificial intelligence-enabled development, and future market opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Stroke Market Overview
• 1.3 Key Findings
  • 1.3.1 Epidemiology Highlights
  • 1.3.2 Current Treatment Landscape
  • 1.3.3 Emerging Therapy Trends
  • 1.3.4 Market Growth Opportunities
• 1.4 Analyst Perspective
• 1.5 Strategic Recommendations

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Stroke
  • 2.1.1 Definition and Clinical Background
  • 2.1.2 Disease Burden
  • 2.1.3 Pathophysiology
• 2.2 Stroke Classification
  • 2.2.1 Ischemic Stroke
  • 2.2.2 Hemorrhagic Stroke
    • 2.2.2.1 Intracerebral Hemorrhage
    • 2.2.2.2 Subarachnoid Hemorrhage
  • 2.2.3 Transient Ischemic Attack (TIA)
• 2.3 Risk Factors and Comorbidities
  • 2.3.1 Hypertension
  • 2.3.2 Atrial Fibrillation
  • 2.3.3 Diabetes Mellitus
  • 2.3.4 Dyslipidemia
  • 2.3.5 Obesity
  • 2.3.6 Smoking and Alcohol Use
• 2.4 Epidemiology Analysis
  • 2.4.1 Global Prevalence
  • 2.4.2 Global Incidence
  • 2.4.3 Mortality Analysis
  • 2.4.4 Disability-Adjusted Life Years (DALYs)
  • 2.4.5 Recurrence Rates
• 2.5 Epidemiology by Stroke Type
  • 2.5.1 Ischemic Stroke Epidemiology
  • 2.5.2 Hemorrhagic Stroke Epidemiology
  • 2.5.3 TIA Epidemiology
• 2.6 Epidemiology by Age Group
• 2.7 Epidemiology by Gender
• 2.8 Diagnosed and Treated Patient Pool Analysis
• 2.9 Epidemiology Forecast

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Rising Global Stroke Burden
  • 3.2.2 Aging Population
  • 3.2.3 Increasing Awareness and Early Diagnosis
  • 3.2.4 Expansion of Stroke Centers
  • 3.2.5 Advancements in Reperfusion Therapies
• 3.3 Market Restraints
  • 3.3.1 Limited Therapeutic Window
  • 3.3.2 High Treatment Costs
  • 3.3.3 Access Disparities
  • 3.3.4 Clinical Trial Challenges
• 3.4 Market Opportunities
  • 3.4.1 Neuroprotection Therapies
  • 3.4.2 Regenerative Medicine Approaches
  • 3.4.3 AI-Enabled Stroke Management
  • 3.4.4 Precision Medicine
• 3.5 Market Challenges
• 3.6 Porter's Five Forces Analysis
• 3.7 PESTLE Analysis
• 3.8 Value Chain Analysis
• 3.9 Unmet Needs Assessment

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Reimbursement Landscape
• 4.3 Pricing Analysis
• 4.4 Health Technology Assessment Trends
• 4.5 Stakeholder Analysis
  • 4.5.1 Physicians
  • 4.5.2 Hospitals
  • 4.5.3 Payers
  • 4.5.4 Patients
• 4.6 Patient Journey Analysis
• 4.7 Treatment Adoption Trends

5. Innovation & Pipeline Landscape

• 5.1 Innovation Overview
• 5.2 Emerging Therapeutic Modalities
  • 5.2.1 Small Molecules
  • 5.2.2 Monoclonal Antibodies
  • 5.2.3 Cell Therapies
  • 5.2.4 Gene-Based Therapies
  • 5.2.5 Neuroprotective Agents
• 5.3 Pipeline Analysis by Development Stage
  • 5.3.1 Discovery and Preclinical
  • 5.3.2 Phase I
  • 5.3.3 Phase II
  • 5.3.4 Phase III
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 Thrombolytic Enhancement
  • 5.4.2 Neuroprotection
  • 5.4.3 Anti-Inflammatory Approaches
  • 5.4.4 Stem Cell-Based Regeneration
  • 5.4.5 Vascular Repair and Remodeling
• 5.5 Pipeline Analysis by Modality
• 5.6 Clinical Trial Landscape
  • 5.6.1 Active Clinical Trials
  • 5.6.2 Completed Clinical Trials
  • 5.6.3 Upcoming Milestones
• 5.7 Licensing, Partnerships, and Collaborations
• 5.8 Funding and Investment Trends
• 5.9 Future Innovation Outlook

6. Treatment Landscape

• 6.1 Current Standard of Care
• 6.2 Treatment Algorithm
• 6.3 Acute Stroke Management
  • 6.3.1 Intravenous Thrombolysis
  • 6.3.2 Mechanical Thrombectomy
  • 6.3.3 Antiplatelet Therapy
  • 6.3.4 Anticoagulation Therapy
• 6.4 Secondary Prevention Strategies
• 6.5 Rehabilitation and Recovery Approaches
• 6.6 Approved Drug Landscape
  • 6.6.1 Alteplase
  • 6.6.2 Tenecteplase
  • 6.6.3 Aspirin
  • 6.6.4 Clopidogrel
  • 6.6.5 Ticagrelor
  • 6.6.6 Rivaroxaban
  • 6.6.7 Apixaban
  • 6.6.8 Dabigatran
  • 6.6.9 Edoxaban
• 6.7 Emerging Therapies Assessment
• 6.8 Comparative Clinical Assessment

7. Global Stroke Emerging Therapies Report Size & Forecast

• 7.1 Market Size Analysis (Historical)
• 7.2 Market Forecast Methodology
• 7.3 Market Revenue Forecast
  • 7.3.1 By Therapy Type
  • 7.3.2 By Stroke Type
  • 7.3.3 By Route of Administration
  • 7.3.4 By End User
• 7.4 Market Attractiveness Analysis
• 7.5 Scenario Analysis

8. Global Stroke Emerging Therapies Report Segmentation

• 8.1 By Stroke Type
  • 8.1.1 Ischemic Stroke
    • 8.1.1.1. Thrombotic
    • 8.1.1.2. Embolic
  • 8.1.2 Hemorrhagic Stroke
  • 8.1.3 Transient Ischemic Attack
  • 8.1.4 Others
• 8.2 By Drug Type
  • 8.2.1 Thrombolytics
  • 8.2.2 Antiplatelets
  • 8.2.3 Anticoagulants
  • 8.2.4 Antihypertensives
  • 8.2.5 Others
• 8.3 By Therapy Type
  • 8.3.1 IV Medication
  • 8.3.2 Endovascular Therapy
  • 8.3.3 Surgical Procedures
    • 8.3.3.1 Mechanical Thrombectomy
    • 8.3.3.2 Carotid Endarterectomy (CEA)
    • 8.3.3.3 Other Emerging Therapies
• 8.4 By Severity Type
  • 8.4.1 Mild
  • 8.4.2 Moderate
  • 8.4.3 Severe
• 8.5 By End User
  • 8.5.1 Hospitals
  • 8.5.2 Specialty Clinics
  • 8.5.3 Rehabilitation Centers
  • 8.5.4 Others

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size and Forecast
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Forecast
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Forecast
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Forecast
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Forecast
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Landscape
  • 10.1.5 Key Companies and Products Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa
  • 10.16.1 Market Size
  • 10.16.2 Epidemiology
  • 10.16.3 Regulatory Framework
  • 10.16.4 Reimbursement Landscape
  • 10.16.5 Key Companies and Products Presence

11. Regulatory & Policy Landscape

• 11.1 Regulatory Overview
• 11.2 United States (FDA)
  • 11.2.1 Drug Approval Pathways
  • 11.2.2 Expedited Programs
• 11.3 Europe (EMA)
  • 11.3.1 Centralized Approval Process
  • 11.3.2 Market Authorization Framework
• 11.4 Japan (PMDA)
• 11.5 India (CDSCO)
• 11.6 China (NMPA)
• 11.7 Orphan and Special Designations
• 11.8 Clinical Trial Regulations
• 11.9 Pharmacovigilance Requirements
• 11.10 Future Regulatory Trends

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Positioning Analysis
• 12.4 Pipeline Competitiveness Assessment
• 12.5 Strategic Initiatives
  • 12.5.1 Mergers and Acquisitions
  • 12.5.2 Collaborations and Partnerships
  • 12.5.3 Licensing Agreements
  • 12.5.4 R&D Investments
• 12.6 SWOT Analysis
• 12.7 Key Success Factors

13. Company Profiles

• 13.1 Genentech
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products: Activase (alteplase), TNKase (tenecteplase)
  • 13.1.3 Key Indications
  • 13.1.4 Stroke-Related Development Activities
  • 13.1.5 Strategic Outlook
• 13.2 Boehringer Ingelheim
  • 13.2.1 Company Overview
  • 13.2.2 Approved Products: Actilyse (alteplase), Pradaxa (dabigatran)
  • 13.2.3 Key Indications
  • 13.2.4 Relevant Pipeline Programs
  • 13.2.5 Strategic Outlook
• 13.3 F. Hoffmann-La Roche Ltd
  • 13.3.1 Company Overview
  • 13.3.2 Approved Products and Neurology Portfolio Overview
  • 13.3.3 Key Indications
  • 13.3.4 Relevant Pipeline Programs
  • 13.3.5 Strategic Outlook
• 13.4 Novartis AG
  • 13.4.1 Company Overview
  • 13.4.2 Approved Products: Entresto (sacubitril/valsartan)
  • 13.4.3 Key Indications
  • 13.4.4 Relevant Pipeline Programs
  • 13.4.5 Strategic Outlook
• 13.5 Bayer AG
  • 13.5.1 Company Overview
  • 13.5.2 Approved Products: Xarelto (rivaroxaban)
  • 13.5.3 Key Indications
  • 13.5.4 Relevant Pipeline Programs
  • 13.5.5 Strategic Outlook
• 13.6 Johnson & Johnson
  • 13.6.1 Company Overview
  • 13.6.2 Approved Products: Xarelto (rivaroxaban alliance markets)
  • 13.6.3 Key Indications
  • 13.6.4 Relevant Pipeline Programs
  • 13.6.5 Strategic Outlook
• 13.7 Daiichi Sankyo
  • 13.7.1 Company Overview
  • 13.7.2 Approved Products: Lixiana/Savaysa (edoxaban)
  • 13.7.3 Key Indications
  • 13.7.4 Relevant Pipeline Programs
  • 13.7.5 Strategic Outlook
• 13.8 Sanofi
  • 13.8.1 Company Overview
  • 13.8.2 Approved Products Relevant to Cardiovascular and Neurological Care
  • 13.8.3 Key Indications
  • 13.8.4 Relevant Pipeline Programs
  • 13.8.5 Strategic Outlook
• 13.9 Novo Nordisk
  • 13.9.1 Company Overview
  • 13.9.2 Approved Products: Ozempic (semaglutide), Rybelsus (semaglutide)
  • 13.9.3 Key Indications
  • 13.9.4 Cardiovascular Risk Reduction Programs
  • 13.9.5 Strategic Outlook
• 13.10 AstraZeneca PLC
  • 13.10.1 Company Overview
  • 13.10.2 Approved Products: Brilinta/Brilique (ticagrelor)
  • 13.10.3 Key Indications
  • 13.10.4 Relevant Pipeline Programs
  • 13.10.5 Strategic Outlook
• 13.11 Merck & Co., Inc.
  • 13.11.1 Company Overview
  • 13.11.2 Approved Products Relevant to Stroke Risk Management
  • 13.11.3 Key Indications
  • 13.11.4 Relevant Pipeline Programs
  • 13.11.5 Strategic Outlook
• 13.12 GlaxoSmithKline plc
  • 13.12.1 Company Overview
  • 13.12.2 Approved Products Relevant to Stroke Prevention and Comorbidities
  • 13.12.3 Key Indications
  • 13.12.4 Relevant Pipeline Programs
  • 13.12.5 Strategic Outlook
• 13.13 Eli Lilly and Company
  • 13.13.1 Company Overview
  • 13.13.2 Approved Products: Mounjaro (tirzepatide), Trulicity (dulaglutide)
  • 13.13.3 Key Indications
  • 13.13.4 Cardiometabolic Risk Reduction Programs
  • 13.13.5 Strategic Outlook
• 13.14 AbbVie Inc.
  • 13.14.1 Company Overview
  • 13.14.2 Approved Products Relevant to Neurology Portfolio
  • 13.14.3 Key Indications
  • 13.14.4 Relevant Pipeline Programs
  • 13.14.5 Strategic Outlook

14. Future Outlook

• 14.1 Market Forecast Summary
• 14.2 Future Treatment Paradigm Evolution
• 14.3 Emerging Technologies Impact
• 14.4 Pipeline Commercialization Outlook
• 14.5 Investment Opportunities
• 14.6 Strategic Recommendations
• 14.7 Long-Term Market Outlook

15. Methodology

• 15.1 Research Objectives
• 15.2 Research Design
• 15.3 Secondary Research Methodology
• 15.4 Primary Research Methodology
• 15.5 Data Validation and Triangulation
• 15.6 Forecasting Methodology
• 15.7 Assumptions and Limitations
• 15.8 Abbreviations
• 15.9 References and Data Sources